NextCell Pharma AB comments on the trading halt of 25 April 2019
With respect to Spotlight Stock Market’s decision on 25 April 2019 to halt trading in NextCell Pharma AB's share, the stock market has, in accordance with its regulations, ordered the company to comment on the trading halt.
NextCell's biobank Cellaviva has received permission from IVO to handle stem cells from adipose tissue
NextCell Pharma AB ("NextCell") announces today that its biobank Cellaviva has been granted an extended permit from the Health and Care Inspectorate (IVO), to also handle and store stem cells from adipose tissue. The decision enables the company to launch its new service, stem cell saving for adults.
NextCell and Cellaviva are highlighted by KI Innovations
The stem cell company NextCell Pharma (“NXTCL”) announces that the company and its stem cell bank Cellaviva are highlighted by Karolinska Institutet Innovations as a positive example in its Jubilee book “20 year of innovation @ Karolinska Institutet”. Of nearly 400 innovations, NextCell and a further 19 examples have been selected to represent the social…
NextCell Pharma AB ("NextCell") gives the market updated information before its presentation at ProHearing later today by CEO, Mathias Svahn. Recruitment of patients with type-1 diabetes in the Phase II part of the ProTrans-1 clinical trial with the drug candidate ProTrans is ongoing. An application for a new trial, ProTrans-repeat, has been submitted and Cellaviva's…
Saving of stem cell from births increases significantly for NextCell´s biobank Cellaviva
Stem cell company NextCell Pharma AB (”NXTCL”) announces that Cellaviva’s sales has increased significantly from November 2018 to January 2019, as compared to the corresponding months previous year. It is partly a result of an increasing interest in stem cell saving in Sweden, and partly due to the expansion into Denmark.
First quarter (2018-09-01 till 2018-11-30) · Net sales amounted to SEK 73,745 (158,354). Apart from the accrual effect, sales increased by 7 %. · Operating result amounted to SEK -5,440,809 (-3,210,815). · Earnings per share* amounted to SEK -0.51 (-0.38). · Cash and bank amounted to SEK 10,437,405 (13,365,659). · Solidity** amounted to 87 (59)…
Patients treated with ProTrans in phase II of the clinical trial
NextCell Pharma AB ("NextCell") hereby announces that they today have reached a significant milestone as they have now initiated the second part of the ProTrans-1 clinical trial. In addition to safety, clinical efficacy is evaluated, e.g. whether the patient's own insulin production improves 12 months after treatment with ProTrans compared to placebo. The phase-II part…
NextCell strengthens the organization for continued growth
NextCell Pharma AB ("NextCell") hereby announces that the Board has decided to appoint Sofia Fredrikson to CFO in the company. Sofia Fredrikson will take office starting today. Former CFO, Leo Groenewegen, will continue to work for the company in the newly created role of Business Development Manager. Both Sofia Fredrikson and Leo Groenewegen will be…
ProTrans trial is approved for high dose treatment in the phase II part
The stem cell company NextCell Pharma AB ("NXTCL") today announced that the Swedish Medical Product Agency has approved the amendment for treatment of patients in the ProTrans-1 trial with high dose of ProTrans in the randomized placebo-controlled part.
NextCell Pharma's clinical trial on the TV3 Diabetes gala
Stem cell company NextCell Pharma AB ("NXTCL") announces that the ongoing clinical trial with ProTrans for the treatment of type 1 diabetes, tonight will be highlighted on the Diabetes Gala. A shorter clip will be shown on the gala and a longer version will be available on ViaPlay, Viafree and on the NXTCL website.
Earlier announced directed share issue to Nordic Tech House AB registered at the Swedish Companies Registrations Office
NextCell Pharma AB ("NextCell") hereby announces that the directed share issue to Nordic Tech House AB (”NTH”) has been registered at the Swedish Companies Registrations Office (Bolagsverket). The newly issued shares are under lock-up.